States consider high costs, possible savings of covering weight-loss drugs for their workers

The skyrocketing popularity of weight-loss drugs like Wegovy, one of a class of drugs called GLP-1s, is fast becoming a state budgetary concern. In deciding whether to cover the medications, policymakers must choose between the long-term benefits of reducing obesity among public employees and their families—which could cut spending on the treatment of chronic diseases—and the short-term costs.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup